173 related articles for article (PubMed ID: 27099522)
1. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
Aktas G; Kus T; Kalender ME; Sevinc A; Camci C; Kul S
Onco Targets Ther; 2016; 9():1921-6. PubMed ID: 27099522
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
[TBL] [Abstract][Full Text] [Related]
5. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
J Clin Oncol; 2024 Apr; ():JCO2302110. PubMed ID: 38648575
[TBL] [Abstract][Full Text] [Related]
6. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.
Zhao Y; Wan B; Zhang T; Xu Y; Liu H; Lv T; Zhang F; Zhan P; Song Y
Transl Lung Cancer Res; 2019 Dec; 8(6):829-837. PubMed ID: 32010561
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
10. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
11. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.
Hagmann R; Hess V; Zippelius A; Rothschild SI
J Cancer; 2015; 6(11):1148-54. PubMed ID: 26516363
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
14. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer.
Xiao X; Wang S; Xia S; Zou M; Li Y; Wei Y; Mei Q; Chen Y
Onco Targets Ther; 2015; 8():2209-14. PubMed ID: 26345293
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis.
Shi H; Guo N; Zhao Z; Liu L; Ni T; Zhang J; Lu Y
Front Oncol; 2023; 13():1154685. PubMed ID: 37007093
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
18. Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
Yeung HM; Sreekrishnanilayam K; Meeker C; Deng M; Agrawal S; Abdullah H; Vijayvergia N
J Gastrointest Cancer; 2023 Mar; 54(1):73-79. PubMed ID: 35006522
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for brain metastases from small cell lung cancer.
Reveiz L; Rueda JR; Cardona AF
Cochrane Database Syst Rev; 2012 Jun; (6):CD007464. PubMed ID: 22696370
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
